National Cancer Malaysia Partners Biocon In Offering Affordable Cancer Care For The Underserved
Biocon Biologics Limited, has partnered with the National Cancer Society of Malaysia to launch a Patient Assistance Program (PAP) in Malaysia aimed at improving access to affordable, high-quality biosimilars for underserved cancer patients in Malaysia.
The partnership will see Biocon Biologics providing quality-assured biosimilars from its oncology portfolio, including Trastuzumab, Pegfilgrastim and Bevacizumab, to NCSM, which will manage patient enrolment and medicine supply as part of its healthcare services. This collaboration combines Biocon's expertise in biosimilars with NCSM's community outreach to enhance
cancer care accessibility and affordability in Malaysia.
The program will start with providing Trastuzumab to cancer patients facing treatment delays due to budget constraints.
Ratish Trehan, Head of Commercial – Emerging Markets, Biocon Biologics, said, 'Together, we hope to positively impact thousands of lives and strengthen Malaysia's efforts to deliver inclusive, patient-centric healthcare.'
Biocon Biologics aims to build on its previous success in expanding access to diabetes care in Malaysia, having served over 345,000 patients, and is now focusing on oncology through strategic partnerships like this.
Related
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BusinessToday
21 hours ago
- BusinessToday
National Cancer Malaysia Partners Biocon In Offering Affordable Cancer Care For The Underserved
Biocon Biologics Limited, has partnered with the National Cancer Society of Malaysia to launch a Patient Assistance Program (PAP) in Malaysia aimed at improving access to affordable, high-quality biosimilars for underserved cancer patients in Malaysia. The partnership will see Biocon Biologics providing quality-assured biosimilars from its oncology portfolio, including Trastuzumab, Pegfilgrastim and Bevacizumab, to NCSM, which will manage patient enrolment and medicine supply as part of its healthcare services. This collaboration combines Biocon's expertise in biosimilars with NCSM's community outreach to enhance cancer care accessibility and affordability in Malaysia. The program will start with providing Trastuzumab to cancer patients facing treatment delays due to budget constraints. Ratish Trehan, Head of Commercial – Emerging Markets, Biocon Biologics, said, 'Together, we hope to positively impact thousands of lives and strengthen Malaysia's efforts to deliver inclusive, patient-centric healthcare.' Biocon Biologics aims to build on its previous success in expanding access to diabetes care in Malaysia, having served over 345,000 patients, and is now focusing on oncology through strategic partnerships like this. Related
Barnama
5 days ago
- Barnama
NCCM 2025: MOH To Focus On Lung Health Prevention And AI
KUALA LUMPUR, June 20 (Bernama) -- The Ministry of Health (MOH) is entering the final phase of its National Strategic Plan for Cancer Control Programme 2021–2025, with a renewed focus on strengthening cancer prevention, early detection and sustainable financing. In this regard Health Minister Datuk Seri Dr. Dzulkefly Ahmad said the three-day National Cancer Congress Malaysia (NCCM) 2025, jointly organised by the National Cancer Society of Malaysia (NCSM) and Sunway University starting today, is aligned with the ministry's plan in charting the next chapter of the strategic plan for cancer which is more data-driven, inclusive and forward-looking approach. 'Cancer remains one of the most pressing and devastating challenges in our fight against the pandemic of Non-Communicable Diseases (NCDs). 'According to the National Cancer Registry Report 2017–2021, we now record over 169,000 reported cancer cases, an increase of 47 per cent from the previous cycle. The lifetime risk of cancer has also increased to one in eight Malaysians,' he said during his keynote address at the opening ceremony of NCCM 2025 themed 'Bridging Gaps, Building Hope, Empowering Lives', at Sunway University, Petaling Jaya, here today. Dzulkefly said in response to the rising threat of lung cancer, the ministry introduced the Lung Health Initiative during last year's NCCM which is currently among the top three most common cancers in Malaysia and a leading cause of death. He said Malaysia led the way on the global stage in cancer prevention and early detection with the adoption of the global resolution entitled Promoting and Prioritising an Integrated Lung Health Approach at the 78th World Health Assembly (WHA78), co-sponsored by 15 other WHO member states. 'This is a historic milestone not just for Malaysia, but for global public health. It reflects our belief in a whole-of-planet approach for lung health that integrates prevention, digital innovation, and people-centred care. 'Implementation is already underway, across six states namely Selangor, Penang, Kedah, Pahang, Kelantan and Sabah. Artificial Intelligence (AI) is now being utilised for chest X-rays in selected health clinics and government hospitals for interpretation, improving accuracy and accelerating early detection for lung cancer and other respiratory illnesses,' he said. Dzulkefly also commended National Cancer Society Malaysia (NCSM) for extending the effort through mobile AI X-ray units, which help screen underserved communities and workers in industrial settings.
The Star
17-06-2025
- The Star
Theta Edge bags RM4.4mil mobile x-ray contract from NCSM
PETALING JAYA: Theta Edge Bhd has accepted a letter of award from the National Cancer Society Malaysia (NCSM) for the provision of mobile X-ray equipment worth RM4.38mil. In a filing with Bursa Malaysia, the software company said the X-ray equipment comes with cloud-based connectivity and built-in artificial intelligence for diagnostics and related services based on a usage-based model. 'The contract scope includes procurement, supply, installation, and maintenance of mobile X-ray equipment at NCSM facilities. 'The contract shall be for a period of five years commencing from June 20, 2025.' The company added that the contract is expected to contribute positively to the net assets and earnings per share of Theta and its group of companies for the financial year ending Dec 31, 2025 and onwards until the termination of the contract. 'The company does not foresee any exceptional risk other than the normal operational risks associated with the Contract during the contract period. Nevertheless, the company will take the necessary steps to mitigate the risks as and when they occur.'
